Nicoclonate is a nicotinic acid derivative. It is an antilipidemic drug.

Tamethicillin is a basic ester pro-drug of methicillin (MET) which is converted in the body by non-specific esterases to MET. Tamethicillin was used as an antibacterial agent in the veterinary as a useful alternative for the treatment of mastitis in livestock, especially in mastitis due to beta-lactamase-producing Staphylococcus.

Nemorubicin, a doxorubicin derivative, is a DNA-intercalator, topoisomerase and RNA synthesis inhibitor that was undergoing development with Nerviano Medical Sciences (Nerviano MS; formerly Pharmacia Italia) for the treatment of solid tumours, specifically, the loco-regional treatment of primary liver tumours (hepatocellular carcinoma). The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. Clinical trials were conducted in Europe, US and China with Nemorubicin given at different dose-schedules and by different routes of administration: as single agent by systemic IV route, oral route and by intra-hepatic artery (IHA) infusion alone or in combination with cisplatin.

Oxetacillin was developed as an antibacterial drug that has never been marketed.

Pentorex (Modatrop) is phenylisopropylamine derivative. It is a central adrenergic stimulant drug related to phentermine, which is used as an anorectic to assist with weight loss. Pentorex is sympathomimetic agent.

Pentisomide is an agent structurally related to disopyramide. Pentisomide is a class-I antiarrhythmic agent with a marked effect on depolarization (action of class Ia and Ic) and on repolarization. Pentisomide dose-dependently inhibited ischaemia-reperfusion arrhythmia. Pentisomide had been in phase II clinical trial for the treatment of arrhythmias. The electrophysiologic effects of pentisomide were investigated after intravenous and oral application in patients with drug refractory atrioventricular nodal tachycardia and patients with orthodromic atrioventricular re-entrant tachycardia. If intravenous pentisomide did not prevent induction of the tachycardia, oral pentisomide was not effective either. Long-term treatment with pentisomide had to be discontinued because of possible side effects.

Difemetorex is a stimulant drug of the piperidine class. It was used as an appetite suppressant, anorectic agent. Difemetorex has intolerable side effects such as insomnia, which limited its clinical use.

ORG-34517 (or PT 150), a glucocorticoid receptor antagonist was development by Organon for the treatment of depression. This drug has completed phase II clinical trial for patients with major depression with psychotic features, however, this study was discontinued. In addition, Pop Test Cortisol LLC is developing ORG-34517 for the treatment of alcoholism. Now, this drug is in phase I clinical trial on stage recruiting to evaluate its safety when it is taken concurrently with alcohol.